Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

abstract：:Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

journal_title：Pharmacogenomics

authors： Glunde K,Serkova NJ

更新日期：2006-10-01 00:00:00

abstract：AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

journal_title：Pharmacogenomics

authors： Lee KC,Hudmon KS,Ma JD,Kuo GM

更新日期：2015-01-01 00:00:00

abstract：AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

journal_title：Pharmacogenomics

authors： Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

更新日期：2008-07-01 00:00:00

abstract：:Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (...

journal_title：Pharmacogenomics

authors： Feng Q,Wilke RA,Baye TM

更新日期：2012-04-01 00:00:00

abstract：AIM:We examined whether HLA-DRB1*1501 and four VDR SNPs influence the macrophage response to infection with Mycobacterium tuberculosis (Mtb) via innate immune versus drug treatment or drug delivery mechanisms. MATERIALS & METHODS:Monocyte-derived macrophages from 24 healthy donors were infected with Mtb in vitro. Surv...

journal_title：Pharmacogenomics

authors： Singh AK,Abhimanyu,Yadav AB,Sharma S,Garg R,Bose M,Misra A

更新日期：2013-04-01 00:00:00

abstract：:Drugs used to treat psychiatric disorders, even when taken as directed, fail to provide adequate relief for a sizeable proportion of patients. Despite our advancements in understanding human genetics and development of high-throughput tools to probe variation, pharmacogenomics has yielded marginal ability to predict d...

journal_title：Pharmacogenomics

authors： Smith RM

更新日期：2017-10-01 00:00:00

abstract：:The completion of the first draft of the human genome sequence has revived the old notion that there is no one-to-one mapping between genotype and phenotype. It is now becoming clear that to elucidate the fundamental principles that govern how genomic information translates into organismal complexity, we must overcome...

journal_title：Pharmacogenomics

authors： Huang S

更新日期：2001-08-01 00:00:00

abstract：:The number of reports investigating disease susceptibility based on the carriage of low-penetrance, high-frequency polymorphisms has steadily increased over the last years. Evidence based on meta-analyses of individual case-control studies is accumulating, defining specific individual variations in disease susceptibil...

journal_title：Pharmacogenomics

authors： Tempfer CB,Schneeberger C,Huber JC

更新日期：2004-01-01 00:00:00

abstract：AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...

journal_title：Pharmacogenomics

authors： Hung CC,Chiou MH,Huang BH,Hsieh YW,Hsieh TJ,Huang CL,Lane HY

更新日期：2011-11-01 00:00:00

abstract：AIM:In order to administer antipsychotic medication with the most beneficial outcome, the appropriate drug and dose needs to be identified. Though often not considered in pharmacogenetic studies, dosage plays an important role in treatment outcome. This study set out to analyze the association between 109 SNPs and anti...

journal_title：Pharmacogenomics

authors： Hettige NC,de Moraes GH,Kennedy JL,De Luca V

更新日期：2016-02-01 00:00:00

abstract：:DxS is a pharmacogenomics business operating at the interface between genetic diagnostics and the pharmaceutical industry. The company strategy is to enable pharmacogenomics by the provision of genetic analysis services to the healthcare sector. The services provide support for drug discovery, drug development and als...

journal_title：Pharmacogenomics

authors： Little S

更新日期：2003-01-01 00:00:00

abstract：:The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...

journal_title：Pharmacogenomics

authors： Hall I

更新日期：2012-01-01 00:00:00

abstract：AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...

journal_title：Pharmacogenomics

authors： Blum S,Vardi M,Brown JB,Russell A,Milman U,Shapira C,Levy NS,Miller-Lotan R,Asleh R,Levy AP

更新日期：2010-05-01 00:00:00

abstract：:The advent of multiplexing technologies has raised the possibility that disease states can be defined using discrete genomic and proteomic patterns or signatures. However, this emerging area has been limited by the 'content problem', arising from the uncertainty of which molecules to focus on. The human cluster of dif...

journal_title：Pharmacogenomics

authors： Woolfson A,Ellmark P,Chrisp JS,A Scott M,Christopherson RI

更新日期：2006-07-01 00:00:00

abstract：AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...

journal_title：Pharmacogenomics

authors： Hoffmann AC,Vallböhmer D,Grimminger P,Metzger R,Prenzel KL,Hoelscher AH,Brabender J

更新日期：2010-03-01 00:00:00

abstract：:Comprehensive, personalized medication management and pharmacogenetic testing are important existing opportunities to reduce adverse medication events and improve overall healthcare outcomes. A primary barrier to the adoption of personalized pharmacology is the inadequacy of existing patient records, drug interaction ...

journal_title：Pharmacogenomics

authors： Coleman H,Ashcraft K

更新日期：2008-04-01 00:00:00

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

journal_title：Pharmacogenomics

authors： Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

更新日期：2007-12-01 00:00:00

abstract：INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...

journal_title：Pharmacogenomics

authors： Marsh S,Mallon MA,Goodfellow P,McLeod HL

更新日期：2005-12-01 00:00:00

abstract：:Founded as a spin-off from the University of Vienna in 1999, VBC-GENOMICS Bioscience Research GmbH (LLC) has rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company has focused on the dev...

journal_title：Pharmacogenomics

authors： Schmidt WM

更新日期：2004-06-01 00:00:00

abstract：:While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

journal_title：Pharmacogenomics

authors： Narasimhan S,Lohoff FW

更新日期：2012-03-01 00:00:00

abstract：:Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strat...

journal_title：Pharmacogenomics

authors： Jensen BC,McLeod HL

更新日期：2013-01-01 00:00:00

abstract：:The recent advent of induced pluripotent stem cells has enabled the study of patient-specific and disease-related neurons in vitro and has facilitated new directions of inquiry into disease mechanisms. With these approaches, we now have the possibility of correlating ex vivo cellular phenotypes with individual patient...

journal_title：Pharmacogenomics

authors： Watmuff B,Liu B,Karmacharya R

更新日期：2017-04-01 00:00:00

abstract：AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...

journal_title：Pharmacogenomics

authors： Saab R,Zouk AN,Mastouri R,Skaar TC,Philips S,Kreutz RP

更新日期：2015-11-01 00:00:00

abstract：:PON1 is a key component of high-density lipoproteins (HDLs) and is at least partially responsible for HDL's antioxidant/atheroprotective properties. PON1 is also associated with numerous human diseases, including cardiovascular disease, Parkinson's disease and cancer. In addition, PON1 metabolizes a broad variety of s...

journal_title：Pharmacogenomics

authors： Kim DS,Marsillach J,Furlong CE,Jarvik GP

更新日期：2013-09-01 00:00:00

abstract：:CYP2D6*84 was first described in a Black South African subject, however, its function remains unknown. Astrolabe, a probabilistic scoring tool developed in our laboratory to call genotypes from whole genome sequence, identified CYP2D6*84 in a trio. The father presented with intermediate metabolism when challenged with...

journal_title：Pharmacogenomics

authors： Gaedigk A,Twist GP,Farrow EG,Lowry JA,Soden SE,Miller NA

更新日期：2017-04-01 00:00:00

abstract：:Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

journal_title：Pharmacogenomics

authors： John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

更新日期：2017-06-01 00:00:00

abstract：:The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well...

journal_title：Pharmacogenomics

authors： Hoffmann MM,Winkelmann BR,Wieland H,März W

更新日期：2001-05-01 00:00:00

abstract：:Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

journal_title：Pharmacogenomics

authors： Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

更新日期：2008-12-01 00:00:00

abstract：:Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

journal_title：Pharmacogenomics

authors： Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

更新日期：2006-04-01 00:00:00